Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.
about
Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells.Late thrombosis associated with drug-eluting stentsDual antiplatelet therapy and drug eluting stents: a marriage of convenienceNeointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomographyRapamycin regulates the expression and activity of Krüppel-like transcription factor 2 in human umbilical vein endothelial cellsMacromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary interventionEfficacy and safety of low-dose clopidogrel after 12-month dual antiplatelet therapy for patients having drug-eluting stent implantation.Long-term outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice: a Canadian experience.Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy.The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial3,3'Diindolylmethane suppresses vascular smooth muscle cell phenotypic modulation and inhibits neointima formation after carotid injury.Selective versus exclusive use of drug-eluting stents in treating multivessel coronary artery disease: a real-world cohort study.Stent thrombosis is the primary cause of ST-segment elevation myocardial infarction following coronary stent implantation: a five year follow-up of the SORT OUT II study.Real-world safety and effectiveness outcomes of a zotarolimus-eluting stent: final 3-year report of the RESOLUTE International study.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Percutaneous coronary interventions with drug eluting stents for diabetic patientsProspective study to evaluate safety and efficacy of Zotarolimus Eluting Stent (PSEZES) in patients with long coronary artery lesions.Rapamycin impairs endothelial cell function in human internal thoracic arteries.Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis.Sirolimus-eluting coronary stents: a review.Intravascular ultrasound to guide percutaneous coronary interventions: an evidence-based analysis.Update on drug-eluting coronary stents.Pathophysiology of coronary thrombus formation and adverse consequences of thrombus during PCI.Effectiveness of Two-Year versus One-Year Use of Dual Antiplatelet Therapy in Reducing the Risk of Very Late Stent Thrombosis after Drug-Eluting Stent Implantation.A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease.An overview of the TAXUS Express, paclitaxel-eluting stent clinical trial program.Efficacy and safety of drug-eluting stents: current best available evidence.Promoting vascular regeneration as an alternative to conventional angioplasty-based intervention.Late thrombosis a concern with drug-eluting stents.Drug-eluting stents in the management of peripheral arterial diseaseVery late stent thrombosis after drug-eluting stent implantation in a patient without aspirin and clopidogrel resistanceAntiplatelet therapy in the era of drug-eluting stents: current and future perspectives.Update on stents: recent studies on the TAXUS stent system in small vessels.Comparison of one-year clinical outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice.Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds.Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularizationFrequency of Vascular Inflammation and Impact on Neointimal Proliferation of Drug Eluting Stents in Porcine Coronary Arteries.Organ transplantation and drug eluting stents: Perioperative challenges.Coronary stent thrombosis in patients with chronic renal insufficiency.Paclitaxel-eluting stents.
P2860
Q24815293-F2815AA5-2F0A-45C2-AA48-D8067BFD685CQ28188113-57415E1A-CF31-41FE-907C-F247F91BADDEQ28222394-2C86CBE1-8A27-437C-BD96-DB1AD95612F0Q28222520-567B8734-E118-4AC6-BDB3-389CC4467BFBQ28482627-9D637FC7-7500-469F-A2D3-7236FE0445E4Q28654633-B1235BDB-68A6-4DFB-9715-F1AFDBCAD94DQ33586022-000B71CA-A850-46C6-B159-F601DD7AE5E4Q33776103-090A4BB5-2520-491E-8FB7-ECC617C6242FQ33992746-58E52421-4D82-47DF-AE88-0D0562128BD1Q34045269-38C6684D-D813-4DAD-B41E-C85DA96C461EQ34233778-61B2D26A-78B6-4435-AD68-F7663A4F9301Q34304853-792441DC-86E5-45F5-8338-E2F1B7FAB84CQ34542615-97D74033-A455-4825-A738-B1C2E9C58A9AQ34548825-21E2C2E9-4CCC-4ACF-8818-0362B2A90ECCQ34771381-7A85A422-9C4F-48F5-9C43-D9D55463378EQ35771445-C9DE0E8C-B535-48FF-8D70-7B871D25DE71Q35830571-B8B35739-2A76-49A5-AB38-0442D43D0620Q35852325-A872108A-ED35-4113-AF46-D49E19B95028Q35927338-C0686C91-A81D-4792-9CE7-C47783000F5DQ36013104-DDD5EAE4-BE13-48B3-B01F-A5C47763DDD4Q36046996-BF68DDCB-3E5B-437E-86B6-95085FB300E2Q36266053-134EECCB-66DA-4732-834B-1C34E429BEB0Q36302119-A76D5111-0C5F-4F47-AE00-9D5B0089F6E3Q36305145-DA04DEC2-B047-49BB-A54E-704FC6091739Q36488244-757962F1-0207-41B7-93E0-3EE7E1B5E666Q36614126-68C24F71-B924-4ACD-876F-0F8EF69237ADQ36639071-4FE64DCA-EE5C-46AB-8E7E-ECEF0B0CEFE5Q36684479-3C669C90-3590-4E48-9E21-37D465685855Q36735679-542F8D91-4C50-4023-9791-F485F3302B8EQ36835836-80838E3C-4B1E-4368-BAC2-E1458ED0D1D0Q36854510-33F4E0AC-A7C8-400D-8B92-38A907AE9575Q36941850-EEFE2CC2-F73A-48B0-8D47-159928304051Q36985317-BA111499-271F-45C7-A2B9-84214EC56DAEQ37098303-5EE00A3C-72AC-4A00-B8B9-B86E3A87CC1DQ37109628-6A6E9B32-6F16-4B8F-B699-988C519497E6Q37167506-F6D37354-8782-4620-BF0D-D4AAF087D3F7Q37314517-87D4852F-DC55-4326-B650-8C14FB1C7289Q37522553-292F67B8-FBD4-406B-8473-95511BF0D085Q37582058-8D794863-2DBE-448B-B87D-EE25F49ACF6AQ37608478-49F1435B-408C-4F10-8BB6-817AA76389E2
P2860
Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Drug-eluting stent thrombosis: ...... cluding 10 randomized studies.
@en
Drug-eluting stent thrombosis: ...... cluding 10 randomized studies.
@nl
type
label
Drug-eluting stent thrombosis: ...... cluding 10 randomized studies.
@en
Drug-eluting stent thrombosis: ...... cluding 10 randomized studies.
@nl
prefLabel
Drug-eluting stent thrombosis: ...... cluding 10 randomized studies.
@en
Drug-eluting stent thrombosis: ...... cluding 10 randomized studies.
@nl
P2093
P1476
Drug-eluting stent thrombosis: ...... cluding 10 randomized studies.
@en
P2093
Camino Bañuelos
Carlos Macaya
Cristina Fernández
Dominick J Angiolillo
Fernando Alfonso
Javier Escaned
Manel Sabaté
Raúl Moreno
Rosana Hernández
P304
P356
10.1016/J.JACC.2004.11.065
P407
P577
2005-03-01T00:00:00Z